CytoMed Therapeutics Receives Nasdaq Notice Over Minimum Bid Price Deficiency
CytoMed Therapeutics (GDTC) has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement. The company's stock closed below $1 for 30 consecutive business days, triggering a notice from the exchange. CytoMed now has until April 5, 2027, to bring its closing bid price back into compliance. This development could pose risks for investors and may affect investor confidence in the company’s ability to maintain listing standards on Nasdaq. Companies often take measures such as issuing a reverse stock split or raising capital through equity offerings to address this issue.
Topics: nasdaq compliance stock delisting risk
Read the full article at Seeking Alpha
Part of the story Taoping Notifies of Nasdaq Minimum Bid Price Deficiency (7 articles)